Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

KVAC

Keen Vision Acquisition Corp

Dec 13 • 04:00PM ET

10.94

Dollar change +0.01
Percentage change 0.09	%

Financial • Shell Companies • USA • NASD

Scroll to Statements

Index	-	P/E	25.32	EPS (ttm)	0.43	Insider Own	20.13%	Shs Outstand	19.37M	Perf Week	0.64%
Market Cap	211.91M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	15.47M	Perf Month	1.30%
Income	8.37M	PEG	-	EPS next Q	-	Inst Own	73.05%	Short Float	0.01%	Perf Quarter	2.53%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.01	Perf Half Y	4.18%
Book/sh	8.15	P/B	1.34	EPS next Y	-	ROA	5.32%	Short Interest	0.00M	Perf Year	7.68%
Cash/sh	0.00	P/C	5297.69	EPS next 5Y	-	ROE	5.42%	52W Range	10.31 - 10.93	Perf YTD	5.87%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	5.30%	52W High	0.09%	Beta	-0.03
Dividend TTM	-	Quick Ratio	0.19	Sales past 5Y	0.00%	Gross Margin	-	52W Low	6.06%	ATR (14)	0.02
Dividend Ex-Date	-	Current Ratio	0.19	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	79.58	Volatility	0.07% 0.13%
Employees	2	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	610.13%	Payout	0.00%	Rel Volume	0.01	Prev Close	10.93
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	78.45K	Price	10.94
SMA20	0.55%	SMA50	1.24%	SMA200	3.34%	Trades		Volume	500	Change	0.09%

Dec-10-24 08:00AM	Medera's Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing (GlobeNewswire)
Oct-31-24 08:00AM	Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology (PR Newswire)
Oct-24-24 08:00AM	Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction (PR Newswire)
Sep-05-24 11:57AM	Medera to List on NASDAQ After Merger with Keen Vision Acquisition Corp. (Exec Edge)
08:00AM	Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation (PR Newswire)

Keen Vision Acquisition Corp. is a blank check company, which engages in effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, and reorganization or similar business combination. The company was founded on June 18, 2021 and is headquartered in Summit, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KVAC

Keen Vision Acquisition Corp

Upgrade your FINVIZ experience